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Background: Uromodulin is the most abundant protein in healthy human urine. 
Recently it has been suggested as a specific biomarker of renal tubular damage. 
We have developed a novel pseudo multiple reaction monitoring (pseudo MRM) 
for the protein’s quantification in human urine. Results: Selection of two peptides 
allowed quantification of uromodulin in human urine. The pseudo MRM quantified 
uromodulin in healthy individuals between 21 and 1344 nM and in autosomal 
dominant tubulointerstitial kidney disease-UMOD patients between 2 and 25 nM. 
Conclusion: The pseudo MRM allows greater confidence in assay specificity than 
traditional MRM methods and quantified uromodulin at concentrations higher than 
achievable by ELISA. Differences in urinary uromodulin concentration related to the 
rs4293393 promoter variant in the UMOD gene was confirmed. This method will be 
used to further investigate uromodulin as a biomarker of renal injury.
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Uromodulin (Tamm–Horsfall protein) is 
a protein that is exclusively synthesized by 
the renal tubular epithelial cells lining the 
thick ascending limb (TAL) of the loop of 
Henle [1]. After synthesis uromodulin is pre-
dominantly trafficked to the apical mem-
brane, where it is cleaved, released into the 
urine and subsequently assembles into poly-
meric filaments. Uromodulin represents the 
most abundant protein in urine of healthy 
individuals, with an estimated production 
rate of 50–100 mg/day [2].
Although the first reports describing uro-
modulin were published in 1950 [3], its biolog-
ical functions are still not fully understood. 
Studies using knockout mice have shown 
uromodulin to regulate NaCl reabsorption by 
the kidney tubule [4,5], protect against urinary 
tract infection and prevent the formation of 
kidney stones [6]. Furthermore, mutations 
in the UMOD gene cause rare, autosomal 
dominant tubulointerstitial kidney disor-
ders [7]. Uromodulin has also been suggested 
as a unique marker of renal tubular function. 
This is a consequence of its exclusive produc-
tion in the TAL, which plays a major role in 
the handling of sodium and divalent cations, 
as well as in urinary concentrating ability. 
Supporting this hypothesis, recent popula-
tion-based studies have demonstrated positive 
associations of urinary uromodulin concen-
tration with urinary electrolytes, osmolality 
and kidney dimensions [8,9]. This indicates 
that uromodulin excretion could represent 
a useful marker of tubular function, and its 
potential utility in  monitoring renal function 
in clinical practice.
In order to definitively ascertain uromod-
ulin’s functions in man, as well as to provide 
suitable assessment into its potential utility 
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Figure 1. Domain structure of uromodulin. Uromodulin contains a 23 amino acid pre-pro sequence, three 
epidermal growth-like factor domains (I, II, III), a domain of 8 cysteine residues (D8C), an N- and C-terminal zona 
pellucida (ZP-N, ZP-C) domain and a glycosylphosphatidylinositol (GPI) anchoring site (red box). Uromodulin has 
seven experimentally verified N-glycosylation sites at Asn 52, Asn 56, Asn 208, Asn 251, Asn 298, Asn 372 and Asn 
489 (marked with asterisks). The arrows represent uromodulin peptides identified following proteolysis of human 
urine. The peptides STEYGEGYACDTDLR and DWVSVVTPAR were further used for the pseudo MRM assay.
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to serve as a biomarker, accurate quantification of the 
protein in urine is required. Currently, uromodulin 
is almost exclusively measured by immunoassay, and 
predominantly quantified by ELISA. ELISAs however, 
may have potential liabilities affecting their accurate 
measurement of uromodulin. Approximately 38% of 
uromodulin’s mass has been attributed to N-glyco-
sylation [10,11]. Eight sites of potential N-glycosylation 
have been identified, with seven of these experimen-
tally verified (Figure 1) [12]. O-glycosylation of uro-
modulin has also been demonstrated [11,13], but this 
only accounts for a minor fraction of the protein’s total 
glycosylation. These post-translational modifications 
of the protein may potentially mask sites of antibody 
binding. Additionally, the protein’s propensity to form 
aggregates, particularly in high ionic strength buffers 
and matrices, as is found in urine, may also result in 
masking of antibody binding sites as well as leading to 
the precipitation of the protein. Consequently we have 
looked to develop a mass spectrometric-based method 
for the quantification of uromodulin in human urine.
Urine represents a challenging matrix for the quanti-
tation of proteins using mass-spectrometry (MS). It con-
tains a low total protein concentration, high amounts of 
salts and other potentially interfering components. Fur-
thermore, samples often exhibit high inter- and intra-
individual variability [14]. While mass-spectrometric 
quantification of proteins in urine have previously 
been reported, these methods generally required pro-
tein enrichment from large urinary volumes [15], frac-
tionation [16] or protein precipitation and clean-up [17]. 
Furthermore they also generally utilize standard multi-
ple reaction monitoring (MRM)  methods on triple 
 quadrupole mass spectrometers.
We have decided to investigate the utility of MS 
for the quantification of uromodulin in human urine. 
Utilizing an LTQ Orbitrap mass-spectrometer we have 
developed a simple pseudo multiple reaction monitor-
ing method (pseudo MRM) to quantify uromodulin 
concentrations in human urine. Following detailed 
validation of the method and comparison with ELISA, 
urinary uromodulin concentration in a human cohort 
was assessed. This cohort exhibited a single nucleotide 
polymorphism in the UMOD promotor, namely the 
rs4293393 variant. This variant has two alleles: T, the 
reference allele, which has a population frequency in 
the European population of 80%, and C, the rare allele 
(based on the reverse strand) [18]. In vitro experiments 
have revealed the homozygous rs4293393-T genotype 
(TT) to result in increased transcription of the UMOD 
gene in comparison to the homozygous rs4293393-C 
genotype (CC) [19]. This increased renal transcription 
in individuals exhibiting the TT genotype has been 
shown to result in greater urinary uromodulin concen-
tration [19,20], alongside an increased risk for develop-
ment of chronic kidney disease (CKD), salt-sensitive 
hypertension and gout, but a reduced risk of kidney 
stone formation [18,19,21]. Subsequently, we then looked 
to investigate whether the pseudo MRM assay could 
quantify uromodulin in urine samples taken from 
autosomal-dominant tubulointerstitial kidney disease-
UMOD (ADTKD-UMOD) patients [22], a clinical sit-
uation where urinary uromodulin concentrations are 
very low [23–26].
Upon submission, it was noted that a similar manu-
script detailing an approach for the quantification of 
uromodulin in human urine by MRM [27], had just 
been published. In the present manuscript we describe 
a simple method that enables us to directly deduce sur-
rogate peptides from data-dependent analysis of urine 
digests allowing the quantification of uromodulin by 
pseudo MRM analyses on the same instrument. The 
assay described here is nearly eightfold more sensi-
tive than the most sensitive transition described by 
the recently published method, and over 20 fold more 
sensitive than their next sensitive transitions [27]. In 
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addition, we validate our method and confirm its bio-
logical relevance by comparing uromodulin excretion 
in a cohort carrying the rs4293393-T or -C UMOD 
promotor variant and in ADTKD-UMOD patients.
Materials & methods
Urine collection
Mid-flow urine samples were collected either from 
healthy male volunteers (aged between 25 and 48 
years) or from a cohort sample pool of individuals 
genotyped for their rs4293393 allele variant [19]. The 
remaining four urine samples analyzed in this study 
were taken from patients diagnosed with ADTKD-
UMOD, with genotyping confirming patients were 
of the C77Y [28] or C126R [28] lineages. Urinary uro-
modulin concentration in these samples was originally 
quantified by ELISA [29] in the range of 253.8 pM to 
2.11 nM [23]. All samples from healthy volunteers were 
immediately aliquoted and stored at -80°C, excepting 
ten of the 30 samples which underwent several freeze–
thaw cycles and storage at -80°C for 2 years. Samples 
from ADTKD-UMOD were immediately aliquoted 
and stored at -20°C. All individuals provided informed 
consent.
Synthesis of stable isotope-labeled 
STEYGEGYACDTDLR & DWVSVVTPAR peptides
Stable isotope labeled (SIL) 
STEYGEGYACDTDLR[13C615N4] and 
DWVSVVTPAR[13C615N4] uromodulin peptides 
were synthesized and obtained from (Thermo Fisher, 
Ulm, Germany). The purity of the two peptides was 
estimated to be approximately 97% pure and more than 
99% isotopically pure. The precision of the  peptide 
concentration was estimated to be ±25%.
Proteolysis of human uromodulin & urine for 
data-dependent LC–MS/MS analysis
Around 20 μg of commercially obtained purified 
uromodulin from human urine (Millipore, Billerica, 
MA, USA) was dissolved in 50 mM Tris-HCl pH 8.0 
to a concentration of 1 μg/μl. Alternatively a 100 μl 
urine aliquot from the frozen pooled human urine 
was taken. Both the uromodulin and pooled urine 
samples were reduced with 10 mM dithiothreitol for 
1 h at 37°C and alkylated with 50 mM iodoacetamide 
for 15 min at room temperature in the dark. Proteins 
were digested with 2 μg trypsin (TPCK-treated, NJ, 
USA) for 2 h at 37°C. A second 2 μg aliquot of trypsin 
was added and the digestion was incubated overnight. 
The resulting digests were acidified with trifluoroacetic 
acid (TFA) to a final concentration of 1% (v/v). The 
peptides were desalted on a Microspin C18 cartridge 
(The Nest Group, MA, USA) according to manufac-
turer’s instructions. Bound peptides were eluted with 
80% acetonitrile, 0.1% TFA (v/v) and dried in a speed 
vac. The digests were reconstituted in 0.1% acetic 
acid, 0.005% TFA (v/v) (solvent A) for LC–MS/MS 
 analysis (see below).
Data-dependent LC–MS/MS analysis
For data-dependent analyses, uromodulin or urine 
digests were analyzed by capillary LC–MS/MS as pre-
viously described [30]. A 0.075 mm × 150 mm column 
(New Objectives, MA, USA) was packed in-house with 
Reprosil C18 reverse-phase material (2.4 μm particle 
size, Dr Maisch, Ammerbuch-Entringen, Germany) 
and connected to the inlet of an Orbitrap FT hybrid 
mass-spectrometer (Thermo Scientific, Reinach, Swit-
zerland). The solvents used for chromatographic sepa-
ration of peptides were solvent A and solvent B (0.1% 
acetic acid, 0.005% TFA, 80% acetonitrile [v/v]). 
Around 50 fmols of uromodulin digest or 2 μg urine 
digest were injected using a Proxeon nLC capillary 
pump (Thermo Scientific) set to 300 nl/min. Chro-
matographic separation of peptides was achieved using 
a linear gradient from 0 to 40% solvent B in solvent A 
over 95 min. Following this, the percentage of solvent 
B was increased to 75% in 10 min and was maintained 
for 15 min before equilibration of the column to 0% 
solvent B. Eluting peptides were ionized at 2.5 kV and 
the mass-spectrometer was operated in data-dependent 
mode. Precursor scans were performed in the Orbitrap 
with the resolution set to 60,000 and fragment ions 
were mass analyzed in the LTQ instrument. A top ten 
method was run so that the ten most intense precur-
sor ions were selected for fragmentation. Resulting 
MS/MS spectra were searched against the SwissProt 
databank (taxonomy set to H. sapiens) with Proteome 
Discoverer 1.4 (Thermo Scientific) using Mascot 
(Matrix Science, London, UK) as the search engine. 
Precursor ion tolerance was set to 10 ppm and frag-
ment ion tolerance to 0.5 Da. Carbamidomethylation 
of cysteine residues were set to fixed and oxidation of 
methionine residues were selected as variable modifica-
tions, respectively. Peptide search matches were filtered 
to 1%  false-discovery rate (high confidence).
Quantification of uromodulin in human urine 
by pseudo MRM
Stored human urine samples were thawed and 10 or 
100 μl aliquots of urine were reduced and alkylated 
as above. Urinary proteins in the 10 μl assay were 
digested with 0.2 μg endoproteinase Lys-C at 37°C for 
2 h before addition of a further 0.2 μg for 2 h. Fur-
ther digestion was performed with 0.2 μg trypsin for 
2 h at 37°C followed by a second addition of 0.2 μg 
trypsin and incubation overnight. For the 100 μl assay, 
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samples were digested using the same procedure but 2 
μg of the proteases were used. The digests were acidi-
fied with TFA to 1% final concentration and the pep-
tides were desalted on a Microspin C18 cartridge (The 
Nest Group) according to manufacturer’s instructions. 
Bound peptides were eluted with 80% acetonitrile, 
0.1% TFA (v/v) and dried in a speed vac. The 10 μl 
urine digest was dried completely, while evaporating 
the 100 μl digest completely was found to strongly 
interfere with peptide recovery. Therefore the 100 μl 
urine digests were evaporated to approximately 30 μl. 
All samples were then restored to 60 μl volume through 
addition of 0.1% acetic acid, 0.005% TFA (v/v) before 
injection to the mass spectrometer.
To establish a calibration curve, urine from three 
healthy males was pooled, and from this two assays 
for 10 and 100 μl urine aliquots were developed. For 
the 10 μl assay, SIL-STEYGEGYACDTDLR and 
SIL-DWVSVVTPAR peptides ranging from 250 
to 4000 nM (eight calibration points) were spiked 
into 10 μl urine digested with endoproteinase Lys-C 
and trypsin prior to sample desalting. For the 100 μl 
assay, SIL peptides ranging from 1 to 250 nM (ten 
calibration points) were spiked into 100 μl urine 
digests. Quality control (QC) samples used in the 
10 μl assay were generated through spiking SIL pep-
tides into urine digests at 250, 1000 and 4000 nM 
concentrations (n = 5 for each batch of samples run). 
QC samples used in the 100 μl assay were generated 
through spiking SIL peptides into urine digests at 1, 
10, 100 and 250 nM concentrations (n = 5 for each 
batch of samples run).
The 10 and 100 μl urine digests spiked with the 
SIL peptides were analyzed by capillary LC–MS/MS 
as above. The LTQ Orbitrap instrument was operated 
in a pseudo MRM mode. For this, the high-resolution 
Orbitrap scanned in selected ion monitoring (SIM) 
mode at 7500 resolution around the isotope clusters 
of the doubly charged STEYGEGYACDTDLR and 
SIL-STEYGEGYACDTDLR peptides (m/z 868.00 
to 872.00 and 873.00 to 876.00, respectively). Like-
wise, the SIM scan was applied to the doubly charged 
DWVSVVTPAR and SIL-DWVSVVTPAR pep-
tides (m/z 565.00 to 568.00 and 570.00 to 573.00, 
respectively). The LTQ part of the instrument was set 
to fragment the STEYGEGYACDTDLR, and SIL-
STEYGEGYACDTDLR peptides (m/z 868.86 and 
873.86) and scanning the fragment ions from 250 to 
1600 m/z. For the DWVSVVTPAR and SIL-DWVS-
VVTPAR pair, the LTQ was set to the corresponding 
precursor m/zs (565.31 and 570.31) and the fragment 
ions were recorded between 155 to 1200 m/z. The nor-
malized collision energy was set to 35 for all peptides 
and the isolation width of the LTQ was 1.0 m/z.
Quantification of uromodulin
Endogenous and SIL STEYGEGYACDTDLR and 
DWVSVVTPAR peptides were located in the chro-
matogram by extracting the selected ion tracings 
from the SIM scans with 10 ppm mass tolerance. The 
elution position of the two peptide precursors was 
checked by overlaying the precursor ions with selected 
fragment ions or by checking the entire fragmenta-
tion spectra. The peaks corresponding to the correct 
precursors from the SIM scans were then integrated 
using XcaliburTM software version 2.1 (Thermo Scien-
tific, Bremen, Germany). Linear regression lines were 
calculated for the generation of calibration curves. 
From these calibration curves, the SIL peptide con-
centrations of the QC samples were calculated. Cali-
bration curves and QC samples were generated for 
each batch of clinical urine samples assayed using the 
10 μl assay (three batches) and for the 100 μl assay 
(one batch). The accuracy in QC measurement was 
ascertained by the following equation: percent accu-
racy = (A/B) × 100, whereas A is the concentration 
of the SIL peptide in the QC sample calculated from 
the calibration curve, and B is the known concentra-
tion of SIL peptide spiked into the QC sample. Per-
cent precision was calculated through assessment of 
the coefficient of variation of the five QC replicates 
multiplied by 100. The lower limit of quantification 
(LLOQ) of the 10 μl assay was defined as a sample 
in which the mean accuracy and precision of the QC 
samples over the three batches were 100 ± 25% and 
≤25% respectively.
Concentration of uromodulin in clinical urine 
samples was quantified through ascertaining the rela-
tive ratio of the endogenous peptide by the spiked in 
peptide, and then multiplication by the spiked SIL 
peptide concentration. A mean was taken between the 
values achieved by the STEYGEGYACDTDLR and 
 DWVSVVTPAR peptides.
ELISA analysis of uromodulin concentration in 
human urine
ELISAs undertaken in this work were performed as 
previously described [10]. A sheep anti-human uro-
modulin antibody (Meridan Life Science, TN, USA) 
was used as the capture antibody, a mouse mono-
clonal anti-human Tamm-Horsfall protein antibody 
(Cedarlane Laboratories, NC, USA) as the primary 
antibody, and a goat anti-mouse IgG (H+L) horse-
radish peroxidase-conjugated protein (Bio-Rad Lab-
oratories Inc., CA, USA) as a secondary antibody. 
The calibration curve was established using human 
uromodulin (stock solution: 100 μg/ml; END, 
CA, USA). The assay was found to have a limit 
of detection of 42.8 pM and linearity of 1.0. The 
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inter- and intra-assay variation were 3.28 and 5.46% 
respectively. The quantifiable range of the assay 
was between 57.35 pM and 7.35 nM  uromodulin 
 concentration.
Quantification of urinary creatinine 
concentration
For investigating the effect of the UMOD genotype, 
uromodulin concentrations measured by both ELISA 
and pseudo MRM assays were normalized to urinary 
creatinine. This was to control for inter-individual 
variations in urine dilution. Urinary creatinine was 
measured using the Syncron® System Creatinine 
Assay (Unicell Dxc Syncron®, Beckman Coulter, CA, 
USA).
Statistical analysis
All statistical analyses were undertaken using Graph-
Pad Prism Version 5.04 (GraphPad Software, CA, 
USA). To assess correlation between data, a linear 
regression line was drawn, with the slope measured. 
Goodness of fit of the data to the line was assessed by 
the r2 value. To ascertain whether a statistical differ-
ence in the urinary uromodulin concentration normal-
ized to creatinine between the CC and TT genotypes 
was evident, a Shapiro–Wilk test was used to confirm 
the data followed a normal distribution. Consequently 
a Mann–Whitney test was used to identify significant 
differences between the genotypes.
Results
Selection of uromodulin peptides for pseudo 
MRM
To select suitable peptide candidates usable for quanti-
fication, we first analyzed individual digests of human 
uromodulin by data-dependent LC–MS/MS on an 
Orbitrap instrument to obtain proteotypic peptides 
reproducibly detected with large signal and good 
sequence coverage. For this, human urine from a pool 
of healthy individuals was reduced, alkylated and 
subsequently digested using a combination of endo-
proteinase Lys-C and trypsin. From the LC–MS/MS 
analysis, 92 proteins were identified by Proteome Dis-
coverer with uromodulin (or Tamm-Horsfall urinary 
glycoprotein, SwissProt Accesssion P07911) ranked at 
position 4 (data not shown). For uromodulin, 16 pep-
tides were identified (Table 1), covering 25% of the pro-
tein’s sequence. These peptides were found to span all 
domains of uromodulin (Figure 1).
From this list, two uromodulin peptides were selected 
as surrogate peptides for the protein’s quantification. 
Peptides containing methionines and glutamines were 
excluded due to their potential for oxidation and deam-
ination [31]. Furthermore, peptides with a charge greater 
than +2 were also not selected as such fragmentation 
spectra are sometimes not particularly rich in fragment 
ions. Consequently, the STEYGEGYACDTDLR and 
DWVSVVTPAR peptides were selected for the quan-
tification of uromodulin. Neither of these two peptides 
Table 1. Identified uromodulin fragments from the data-dependent analysis of human urine.
Sequence MH+ Charge m/z Mascot ion 
score
Δ ppm
186STEYGEGYAcDTDLR200 1736.7225 2 868.86487 109 8.97
437TALQPMVSALNIR449 1413.8003 2 707.40381 84 8.5
450VGGTGMFTVR459 1024.5307 2 512.76898 79 6.05
589SGSVIDQSR597 948.4809 2 474.74411 75 6.75
532DSTIQVVENGESSQGR547 1705.8122 3 569.27557 75 7.82
143GDGWHcEcSPGScGPGLDcVPEGDALVcADPcQAHR178 3983.6090 4 996.65771 65 9.32
351SLGFDKVFMYLSDSR365 1764.8765 2 882.94189 61 7.88
376DWVSVVTPAR385 1129.6089 2 565.30811 55 7.83
357VFMYLSDSR365 1117.5431 2 559.27521 55 7.55
366cSGFNDR372 855.3483 2 428.17776 47 7.99
548FSVQMFR554 914.4619 2 457.73459 45 7.18
598VLNLGPITR606 982.6114 2 491.80933 42 7.06
437TALQPmVSALNIR449 1429.7955 2 715.40179 41 8.55
520YFIIQDR526 954.5104 2 477.75882 38 6.28
179TLDEYWR185 982.46874 2 491.73801 35 5.94
Lower case c represents carbamidomethylated cysteine residue, and lower case m represents an oxidized methionine residue. Peptides marked in bold represent the
surrogate peptides used in the quantification of uromodulin in human urine.
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Figure 2. Fragmentation of the human uromodulin peptides used for quantification. Fragmentation spectra of the 
STEYGEGYACDTDLR (A) and DWVSVVTPAR (B) peptide fragments identified from human urine tryptic digests. The observed b and y 
ions are labeled in red and blue, respectively.
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contained a site of known N-glycosylation (Figure 1) 
and both yielded intense fragment ions (Figure 2A & B), 
supporting the utility of these peptides as surrogates for 
the quantification of uromodulin in human urine. Fol-
lowing selection of these peptides, SIL peptides of the 
same sequence but labeled at the C-terminal arginine 
using 6C13 and 4N15 isotopes were synthesized. This 
labeling resulted in a +10 Da mass shift compared with 
their unlabeled counterparts.
Pseudo MRM method development & assay 
validation
Following selection of the two surrogate peptides for the 
quantification of uromodulin in urine, an MRM-like 
www.future-science.com 1285future science group
Development & characterization of a pseudo MRM method for the quantification of human uromodulin in urine   Research Article
(pseudo MRM) scanning method on an LTQ Orbi-
trap instrument was developed. A SIM scan around the 
isotope cluster of both the endogenous and SIL forms 
of both peptides was set (Table 2). The ion trap (LTQ) 
of the instrument was set to fragment only the doubly 
charged endogenous and SIL precursors of the peptides 
with a fixed fragment ion scan range set to cover the 
most prominent fragment ions (Table 2).
These pseudo MRM scan parameters were tested by 
spiking the two SIL peptides into 10 μl of digested pooled 
human urine to a final concentration of 100 nM, with 
tandem mass-spectrometric (MS/MS) analysis using 
the scanning parameters outlined above. The result-
ing chromatogram was relatively complex (Figure 3A), 
despite targeted SIM scanning. To locate the position of 
the two uromodulin peptides, the m/z for the doubly-
charged endogenous and SIL STEYGEGYACDTDLR 
and DWVSVVTPAR pairs were extracted with 10 ppm 
tolerance. Both pairs were unambiguously located in 
the chromatogram (left panels of Figure 3B–E) and the 
fragment spectra perfectly matched the sequence of the 
two peptides with the expected 10 Da shift of the y-ions 
for the SIL peptides (right panels of Figure 3B–E). The 
selected ion chromatograms showed that the doubly 
charged STEYGEGYACDTDLR uromodulin peptide 
constituted the major peak (57.32 min) in the total ion 
chromatogram, while the second DWVSVVTPAR pep-
tide produced a less intense, but still a pronounced peak 
at 70.54 min (Figure 3A). Interestingly, a very slight shift 
in retention time of the SIL peptides compared with their 
endogenous counterparts was noticeable (Figure 3B–E). 
Also, the ratio of the intensities for the endogenous and 
SIL peptides was approximately the same for the two 
pairs, indicating that both peptides were equally well 
liberated during the digestion of  uromodulin.
For the calibration curve, SIL peptides were spiked 
into digested human urine at final concentrations of 
between 100–4000 nM (9 points, Figure 4A) and 
analyzed by pseudo MRM. The r2 value for the SIL-
STEYGEGYACDTDLR peptide calibration curve 
was 0.9953 ± 0.0041 (mean ± StDev), and for the SIL-
DWVSVVTPAR was 0.9897 ± 0.0065 (mean ± StDev).
In order to achieve confidence in the reproducibil-
ity and accuracy of the 10 μl assay, as well as defin-
ing its LLOQ, the guidelines of the US Food and 
Drug Administration (FDA) and recommendations 
by Carr et al. [32,33] were followed. The LLOQ of the 
10 μl assay (interassay accuracy of 100 ± 25% and pre-
cision ≤ 25%) was 250 nM. Interday mean accuracy of 
100 ± 20% and precision of ≤ 20% for the 1000 and 
4000 nM QC samples provides further confidence in 
the reliability of the assay (Table 3). In order to quan-
tify urinary uromodulin concentration below 250 nM 
concentration an assay for 100 μl urine was developed.
Upon development of a calibration curve for the 
100 μl urinary uromodulin assay it was found that 
evaporating samples to complete dryness after desalt-
ing the digest meant a linear curve was unachiev-
able. We hypothesize that this is a consequence of 
hindrance from a moiety not removed by desalting 
(matrix effect). This interference could be resolved to 
some extent through evaporating samples to approxi-
mately 30 μl volume, and subsequently restoring all 
samples to 60 μl volume through addition of 0.1% 
acetic acid, 0.005% TFA (v/v). This allowed a calibra-
tion curve between 1 and 200 nM to be achieved for 
SIL-STEYGEGYACDTDLR (r2 = 0.9896, 9 points) 
and between 1 and 250 nM for SIL-DWVSVVTPAR 
(r2 = 0.9723, 10 points) (Figure 4B). However, when 
assessing the precision values of QC samples it was 
noted that the assay was variable (data not shown), 
and therefore validation of the assay as undertaken by 
the 10 μl assay could not be achieved. We suspect that 
to some extent that this may be a consequence of error 
in attempting to reconstitute partially dried samples 
to a universal 60 μl volume. As the same aliquoted 
pooled-urine had been used throughout this work, 
we hypothesized that normalizing the area under the 
curve (AUC) of the SIL-STEYGEGYACDTDLR and 
SIL-DWVSVVTPAR peptides to their endogenous 
versions released through tryptic digest of the urine 
matrix would remove this error from the method. 
This approach allowed an optimal linear standard 
curve for both SIL-STEYGEGYACDTDLR (r2 = 
0.9994, 10 points) and SIL-DWVSVVTPAR (r2 
= 0.9848, 10 points) between 1 and 250 nM to be 
achieved (Figure 4C). Furthermore, also normalizing 
the QC samples in the same way meant that the intra-
Table 2. Operating parameters for the pseudo multiple reaction monitoring assay.
Peptide SIM scan range Parent ion m/z MS2 scan range
STEYGEGYACDTDLR 868.0–872.0 868.8625 250–1600
STEYGEGYACDTDLR* 873.0–876.0 873.8648 240–1600
DWVSVVTPAR 565.0–568.0 565.3042 155–1200
DWVSVVTPAR* 570.0–573.0 570.3081 155–1200
R* represents a [13C615N4] labeled arginine residue.
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Figure 3. Pseudo multiple reaction monitoring of uromodulin in human urine (see facing page). (A) Total ion count of a digest of 
10 μl pooled human urine recorded with a pseudo MRM. Extracted ion chromatograms of (B) the SIL-STEYGEGYACDTDLR (m/z 873.86) 
and (C) endogenous STEYGEGYACDTDLR (m/z 868.86), (D) SIL-DWVSVVTPAR (m/z 570.31) and (E) endogenous DWVSVVTPAR 
(m/z 565.30) doubly charged peptides. The corresponding fragmentation spectra are shown in the right panels. R* represents a 
[13C615N4] labeled arginine residue.
Figure 4. Calibration curves for the SIL peptides spiked into 10 μl and 100 μl digested urine. Increasing concentrations of the 
SIL surrogate peptides were spiked into (A) 10 or (B) 100 μl digested human urine and measured by the pseudo MRM method. 
STEYGEGYACDTDLR (red circles, r2 = 0.9947 for the 10 μl assay and 0.9793 for the 100 μl assay, respectively). DWVSVVTPAR (blue 
squares, r2 = 0.9924 for the 10 μl assay and 0.9723 for the 100 μl assay, respectively). Representative experiments are shown. 
(C) Around 100 μl calibration curve when AUC of SIL-peptides is normalized to their endogenous counterparts. STEYGEGYACDTDLR 
(red circles, 0.9994). DWVSVVTPAR (blue squares, r2 = 0.9848). (D) Increasing concentrations of SIL-STEYGEGYACDTDLR was spiked 
into 100 μl digested urine (green triangles), or 50 mM Tris-buffer pH 8 (red circles), or into a digest of purified uromodulin dissolved 
in 100 μl 50 mM Tris-buffer pH 8 (blue squares).
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assay validation could be undertaken in accordance 
with the guidelines of the FDA and Carr et al. [32,33]. 
The LLOQ of the 100 μl assay (intra-assay accuracy 
of 100 ± 25% and precision ≤25%) was 1 nM for 
STEYGEGYACDTDLR and 10 nM for DWVSV-
VTPAR. Intra-assay mean accuracy of 100 ± 20% 
and precision of ≤20% for the 100 and 250 nM QC 
samples provides further confidence in the reliability 
of the assay (Table 4).
Further investigations into the matrix effect 
of urine in the 100 μl assay were undertaken by 
comparing the intensity of equimolar amounts of 
 SIL-STEYGEGYACDTDLR spiked into either 100 
μl digested pooled urine, or 50 mM Tris buffer pH 
8.0 alone, or purified uromodulin stored in 50 mM 
Tris buffer pH 8.0 (Figure 4C). While the resulting 
AUC for the signal for the SIL-STEYGEGYACDT-
DLR peptide was similar for the endogenous uro-
modulin peptide and the 50 mM Tris buffer spike-in, 
an approximate tenfold loss in signal occurred when 
 SIL-STEYGEGYACDTDLR was spiked into digested 
human urine.
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One concern in quantifying proteins through the 
tryptic release of surrogate peptides is the potential 
for peptide degradation over the digestion period, 
resulting in the introduction of bias into the quantifi-
cation method. To test peptide degradation through-
out the digestion period the SIL peptides (at final 
concentrations of 250, 1000 and 4000 nM, n = 5) 
were spiked into 10 μl reduced and alkylated urine 
immediately prior to addition of the endoproteinase 
Lys-C, and compared with samples where SIL pep-
tides were added at the end of the digestion process 
immediately prior to desalting. No significant differ-
ence in the AUCs from the extracted pseudo MRM 
traces from either peptide was observed throughout 
the digestion process (Supplementary Figure 1). To 
ensure that no loss of peptides occurred when the 
samples are held in the auto sampler throughout LC–
MS/MS analysis of the batches, all QC samples in 
the 10 μl assay (250, 1000 and 4000 nM SIL peptide 
concentrations, n = 5 for each batch) were assayed 
at the start of the batch, and then re-analyzed at the 
end. Again no significant differences in the AUCs 
from the extracted pseudo MRM traces of the SIL 
peptides could be detected throughout the run (data 
not shown).
Validation of the surrogate peptides for 
the quantification of urinary uromodulin 
concentration in individuals exhibiting TT or CC 
genotype
It is almost universally recommended to use more than 
one surrogate peptide in the absolute quantification of 
proteins by MS. This approach allows rapid identifica-
tion of any peptide specific issues with the potential for 
influencing protein quantification. Analysis of the 30 
samples in the cohort revealed a good correlation (r2 = 
0.8696, slope = 1.0408) in urinary uromodulin quan-
tification using either the STEYGEGYACDTDLR or 
the DWVSVVTPAR surrogate peptides (Figure 5A). 
Discrepancy in one point is evident from this correla-
tion analysis, where STEYGEGYACDTDLR is quanti-
fied at 1606 nM concentration, and DWVSVVTPAR 
is quantified at 1279 nM concentration. While this dif-
ference is within the stipulated 20% accuracy criteria of 
the assay, it is most likely a consequence of human han-
dling. The similar quantification of urinary uromodu-
lin by both peptides provides confidence in their suit-
ability as surrogates for the protein. For the assessment 
of urinary uromodulin concentration in this cohort of 
30 individuals a mean value between these two peptides 
was calculated.
Table 4. Intraday assay validation parameters from the 100 μl uromodulin quantification assay.
 Accuracy (% ± StDev) Precision (%)
 STEY DWV STEY DWV
QC1
 
124.46
(± 16.06)
361.22
(± 10.85)
12.90
 
3.00
 
QC2
 
103.78
(± 9.32)
114.57
(± 7.82)
8.98
 
6.82
 
QC3
 
106.12
(± 4.71)
115.68
(± 22.57)
4.44
 
19.49
 
QC4
 
86.15
(± 8.35)
100.65
(± 17.206)
9.69
 
17.10
 
Data represented as mean (± StDev). STEY represents the STEYGEGYACDTDLR peptide, DWV represents the DWVSVVTPAR peptide. QC 1,
2, 3 and 4 refer to quality controls calculated at 1, 10, 100 and 250 nM SIL peptide concentration, respectively.
Table 3. Interday assay validation parameters from the 10 μl uromodulin quantification assay.
 Accuracy, % (± StDev) Precision (%)
 STEY DWV STEY DWV
QC1 118.42 124.71 12.11 8.51
 (± 14.34) (± 10.61)   
QC2 107.96 100.43 14.38 12.93
 (± 15.53) (± 12.99)   
QC3 104.23 100.36 12.10 16.36
 (± 12.61) (± 16.43)   
Data represented as mean (± StDev). STEY represents the STEYGEGYACDTDLR peptide, DWV represents the DWVSVVTPAR peptide. QC 1,
2, 3 refer to quality controls calculated at 250, 1000 and 4000 nM SIL peptide concentration, respectively.
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Figure 5. Quantification of urinary uromodulin in human urine samples by pseudo multiple reaction 
monitoring and ELISA. (A) Correlation of urinary uromodulin concentration in all samples when measured by 
STEYGEGYACDTDLR or DWVSVVTPAR in both genotypes. Correlation (r2 = 0.8696, slope= 1.0408). (B) Correlation 
of urinary uromodulin concentration in all samples when measured by pseudo MRM or ELISA (r2 = 0.7038, slope 
= 0.471). (C) Reproducibility of the pseudo MRM when urinary uromodulin concentration was reassessed in two 
independent assays. Correlation (r2 = 0.9903, gradient = 0.9391, n = 13). (D) Reproducibility of the ELISA method 
when urinary uromodulin concentration was reassessed in two independent assays. Correlation (r2 = 0.5895, slope 
= 0.8332, n = 30). (E) Effect of the promoter variant rs4293393 of UMOD on urinary uromodulin concentration as 
measured by pseudo MRM and ELISA (n = 11 for CC, n = 19 for TT genotypes). Data represented as mean (± StDev). 
*p ≤ 0.02; **p ≤ 0.002.
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Quantification of urinary uromodulin 
concentration in individuals exhibiting either 
TT or CC genotype
Following validation of the pseudo MRM method for 
the quantification of uromodulin in human urine, the 
method was used to quantify urinary uromodulin con-
centration in a cohort of individuals previously assessed 
for their UMOD rs4293393 genotype [20]. Data achieved 
by the pseudo MRM assay were then compared and 
contrasted with that of an established ELISA [10]. Out 
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of the 30 individuals assayed, 11 belonged to the CC 
genotype and 19 to the TT  genotype.
The pseudo MRM quantified urinary uromodulin 
in the 30 clinical urine samples in the range of 21 to 
1344 nM, compared with a range of 39 to 699 nM 
obtained with the ELISA. Generally both this ELISA 
assay and the pseudo MRM quantified urinary uro-
modulin concentrations in the sample cohort similarly 
(r2 = 0.7038, slope = 0.471), however the pseudo MRM 
quantified three samples at much greater values than 
the ELISA (Figure 5B).
To investigate the reproducibility of urinary uro-
modulin quantification using the pseudo MRM 
method, 13 samples that covered the concentration 
range of urinary uromodulin from the initial assay were 
re-analyzed. Excellent reproducibility of the pseudo 
MRM assay was observed (r2 = 0.9951, slope = 0.9903) 
(Figure 5C), providing further confidence in the reli-
ability of the method. Using a similar approach, the 30 
samples were re-analyzed using the ELISA (Figure 5D). 
Reduced correlation between the initial and repeated 
ELISA assays was observed when compared with the 
pseudo MRM method (r2 = 0.5895, slope = 0.8332). 
The reduced correlation between the two ELISA 
measurements was expected, considering the known 
effects of storage duration (up to 2 years) and freezing-
thawing cycles on the determination of uromodulin 
by this method [10]. In contrast, the excellent correla-
tion between the two pseudo MRM analyses however 
does suggest that this method is devoid of these sample 
 stability and freeze–thaw issues affecting the ELISA.
Effect of the UMOD genotype on urinary levels 
of uromodulin
Subsequently the effect of the rs4293393 genotype 
on urinary uromodulin concentration was confirmed 
using the pseudo MRM assay (Figure 5E). In the 
analysis of these 30 samples, both ELISA and pseudo 
MRM assays identified a significant increase in the 
urinary levels of uromodulin in subjects harboring the 
TT or CC genotype (p = 0.001 for pseudo MRM; p 
= 0.0142 for ELISA). The effect of the genotype was 
slightly greater for the pseudo MRM assay than ELISA 
(2.02-fold compared with 1.59-fold, respectively).
Quantification of urinary uromodulin 
concentration in autosomal dominant 
tubulointerstitial kidney disease-uromodulin 
patients
ADTK-UMOD is considered to represent one of the 
clinical situations where urinary uromodulin con-
centration is extremely low after disease onset. Con-
sequently we set out to test our assay and investigate 
whether the pseudo MRM was able to identify, and 
even quantify urinary uromodulin concentration in 
these patients. Urine was collected from four patients 
confirmed by genotyping to suffer from ADTKD-
UMOD and assessed for uromodulin concentration 
using the 100 μl pseudo MRM assay and ELISA.
Urinary uromodulin concentration was only suffi-
cient in patient 4 to allow quantification by both surro-
gate peptides. For the remaining samples, urinary uro-
modulin concentration was below the 10 nM LLOQ of 
the DWVSVVTPAR surrogate peptide. Relying solely 
on the STEYGEGYACDTDLR surrogate peptide uri-
nary uromodulin concentration could be quantified in 
patients 2 and 3. While DWVSVVTPAR could not 
be quantified in these samples, the endogenous peptide 
could be identified through detection of the full frag-
mentation spectra (data not shown). While uromodu-
lin concentration could not be quantified in urine col-
lected from patient 1, fragment ion spectra attributable 
to the endogenous STEYGEGYACDTDLR but not 
DWVSVVTPAR peptide could be identified (data not 
shown). While this sample set is too small for correla-
tion analysis, it appears that both the pseudo MRM 
Table 5. Quantification of urinary uromodulin concentration in autosomal dominant 
tubulointerstitial kidney disease-uromodulin patients by pseudo multiple reaction monitoring or 
ELISA assay.
Patient ID Uromodulin 
polymorphism
Pseudo MRM (nM) ELISA (nM)
1 C126R NQ 1.16
2 C77Y 7.75† 3.24
3 C77Y 2.16† 1.12
4 C77Y 25.21‡ 19.54
NQ represents a sample where urinary uromodulin concentration was below the LLOQ for both peptides, but the STEYGEGYACDTDLR
peptide could be detected through identification of the precursor ion and capture of the appropriate fragment ion scan.
†Represents a sample where the urinary uromodulin concentration was below the LLOQ of the DWVSVVTPAR peptide, and therefore the
protein was quantified only using the STEYGEGYACDTDLR peptide.
‡Represent a sample where both STEYGEGYACDTDLR and DWVSVVTPAR peptides could be used to quantify urinary uromodulin
concentration.
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methods and ELISA quantified uromodulin in these 
samples similarly (Table 5).
Conclusion
Protein quantification by MRM critically hinges on 
the selection of suitable surrogate peptides. It is also 
widely recommended that multiple surrogate peptides 
should be selected for the quantification of a single 
protein [34,35]. This approach allows rapid identifica-
tion of peptide specific issues affecting protein quan-
tification. This is achieved through comparing the 
protein’s quantification between these individual sur-
rogate peptides. We selected an approach whereby we 
searched for surrogate uromodulin peptides in trypsin-
digested human urine. This experiment identified 
16 tryptic peptides for uromodulin, accounting for 
25% of the protein’s sequence. The reasons for this low 
sequence coverage are unclear. Data-dependent analy-
sis of a trypsin-digested commercial preparation of 
human uromodulin allowed only moderately increased 
sequence coverage to 34% (data not shown), suggest-
ing matrix effects of urine are not primarily responsible 
for this low sequence coverage. The protein’s N-glyco-
sylation is also not likely to be an important factor as 
peptide-N-glycosidase F (PNGaseF) mediated degly-
cosylation of a uromodulin standard purified from 
human urine only moderately increased sequence cov-
erage to 43% [36]. This low sequence coverage severely 
restricted the availability of peptides that could be 
investigated for their suitability to act as surrogates. 
However, we were able to select two surrogate peptides 
STEYGEGYACDTDLR and DWVSVVTPAR, for 
the quantification of urinary uromodulin concentra-
tion, based on the fact that they were always observable 
in digests of human urine. As both of these peptides 
quantified human urinary uromodulin concentration 
similarly, in this setting selection of only these two 
 surrogate peptides for quantification is sufficient.
This approach toward selection of surrogate peptides 
varied from that proposed by Fu et al. for the quan-
tification of urinary uromodulin [27]. Fu et al. used 
in silico peptide digestion, with subsequent selection of 
candidate peptides for detailed testing and validation. 
This was necessary because different instruments for 
data-dependent and MRM (Orbitrap and triple-quan-
drupole) analyses were used that did not allow direct 
transfer of usable fragmentation spectra from one 
instrument to the other [27]. However, in our approach, 
the LTQ-Orbitrap mass-spectrometer is used for both 
data-dependent and pseudo-MRM analysis, which 
allows us to exactly predict the fragmentation behavior 
of peptides in the pseudo MRM mode. In peptide selec-
tion, Fu et al. proposed to remove peptides containing 
cysteine residues from consideration as surrogates due 
to concerns over in vitro and in vivo modification. Due 
to the high cysteine content of uromodulin, we feared 
that excluding cysteine residues from consideration 
could cost a large proportion of the potential surrogate 
peptides of the protein. These fears were exacerbated by 
the low-sequence coverage of both uromodulin protein 
standard in buffer and uromodulin in urine. In our 
experience however, the selected STEYGEGYACDT-
DLR peptide proved to represent the most optimal sur-
rogate peptide in our studies as it was identified in all 
data-dependent analyses of both urine and uromodu-
lin standard. The peptide also behaved reproducibly, 
and consistently provided an excellent area under the 
curve signal and peak shape. Conversely, we excluded 
peptides containing asparagine and glutamine residues 
from analysis over concerns that the residue could 
undergo unpredictable deamination [31], resulting in 
the potential introduction of bias into the method. 
However, data by Fu et al., showing the satisfactory use 
of both FVGQGGAR and YFIIQDR as surrogate pep-
tides for urinary uromodulin analysis suggests that this 
concern may also be overly cautious. In summary, both 
approaches allowed the selection of suitable peptides 
for the quantification of uromodulin in human urine.
The appropriate selection and use of standards is 
an important consideration in protein quantification 
by MRM. We selected an approach where synthetic 
SIL peptide standards of the two uromodulin surro-
gate peptides were spiked at a known concentration 
into urine samples following sample digestion, imme-
diately before desalting [37]. In the analysis of urinary 
uromodulin concentration in clinical samples, this 
approach allows normalization for varying peptide 
recoveries following the desalting procedure. However, 
as these same SIL peptides were used in constructing 
calibration curve and QC samples, it is notable that 
exogenous standards were not used in calibration curve 
and QC samples to account for these varying peptide 
recoveries. The absence of such a standard did not dras-
tically affect the validation of the 10 μl assay, although 
it could suggest that our estimation of the LLOQ of 
250 nM may be conservative. This hypothesis is sup-
ported by the good correlation between the analysis of 
the same samples using STEYGEGYACDTDLR in 
the 10 or 100 μl assay (Supplementary Figure 2). Nota-
bly, this correlation was reduced for the DWVSVVT-
PAR peptide. The lack of a further exogenous standard 
however hindered validation of the 100 μl assay. We 
suspect that this is a consequence of the introduction 
of error into the assay, as matrix effects meant that 
samples had to be evaporated to incomplete dryness 
before reconstitution to a universal volume. Precision 
and accuracy of the assay could be restored through the 
normalization of exogenous SIL-peptides in QC and 
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calibration samples to their endogenous counterparts. 
This approach is a far from perfect solution, but it indi-
cates the importance of spiking in a further exogenous 
peptide into calibration and QC samples used in both 
the 10 and 100 μl assays. While this exogenous peptide 
standard need not be a differently labeled SIL-version 
of the surrogate peptides, its similar extraction and 
mass-spectrometric signal to the surrogate peptides 
should be experimentally verified.
The study by Fu et al. described an intricate 
approach for generation of a standard curve through 
spiking increasing concentrations of uromodulin stan-
dard into buffer alongside a constant concentration of 
SIL peptide standards. It is expected that the ratios of 
SIL peptide to endogenous would remain constant in 
both urine and in buffer, therefore allowing accurate 
quantification. However, they also define the LLOQ 
as the lowest point on the calibration curve, where 
recovery is 100 ± 20% and CV is <20%. This value 
was defined as between 7.65 and 21.4 nM urinary 
uromodulin concentration depending on the MRM 
transition [27]. We, however, have proven the increased 
sensitivity of our 100 μl assay with an LLOQ of 1 nM 
for the STEYGEGYACDTDLR peptide and 10 nM 
for the DWVSVVTPAR peptide. Furthermore, as the 
calibration curve generated by Fu et al. is not gener-
ated in urine, the substantial matrix effects observed 
through our experiments would not be accounted for 
in defining the LLOQ of their assay. Consequently the 
LLOQ reported by Fu et al. is likely to be ambitious.
It is also notable that in the strategy that was used 
in our study, no normalization was used to account for 
protein reduction, alkylation and proteolytic enzyme 
digestion. These processes have been estimated to rep-
resent the greatest source of error in quantitative pro-
teomics [38]. An ideal alternative mechanism toward 
the use of standards would be a human uromodulin 
protein standard, completely labeled with, for example, 
13C spiked into urine. However, these protein stan-
dards are expensive, and are not universally available. 
Selevsek et al. reported another approach describing 
the successful utilization of three commercially avail-
able yeast proteins for normalization in targeted urine 
proteomic investigation [17]. Failing this, selecting SIL 
peptides of the surrogates, but adding amino acids 
flanking the trypsin digestion sites has been suggested 
as an approach allowing some normalization for diges-
tion enzyme efficiency. However, these peptides do not 
take into account factors including obstruction of the 
digestion enzyme from access to the digestion site by 
steric hindrance in intact proteins, or by incomplete 
reduction and alkylation, or alternatively if portions of 
the molecule may be aggregated as could be observed 
with uromodulin.
A further concern in targeted quantification of pro-
teins is the specificity of MRM transitions [39]. The 
extensive sample complexity in proteomic workflows 
can introduce interfering signals not attributable to 
the analyte of interest [34]. Utilizing this pseudo MRM 
approach with high-resolution mass-spectrometers 
(HRM), including the Orbitrap-LTQ, a selected pre-
cursor ion is isolated and subsequently fragmented in 
the collision cell, with the mass of all resulting frag-
ments analyzed. This allows the full fragmentation 
MS/MS of the peptide of interest to be captured and 
throughout all analyses complete specificity of the 
transition can be verified and assured.
Further investigations were undertaken to identify 
matrix effects of urine on the signal of the SIL peptides 
in the 100 μl assay. Drying samples to completeness 
after desalting greatly interfered with the assay, mak-
ing a linear calibration curve unachievable. We suspect 
that this may be attributed to urobilin, as a yellow-
brown pigment deriving from urine was found to be 
retained on the cartridge upon desalting until elution. 
Upon evaporating samples to dryness, this moiety 
could not be resolubilized, and may have prevented 
solubilization of the surrogate peptides. However, 
further experimentation is required to define whether 
this yellow pigmented moiety is directly responsible 
for this matrix effect. This interaction was resolved by 
not evaporating samples to dryness after desalting, and 
subsequently restoring samples to a universal volume.
Despite resolving the issue with peptide resolubiliza-
tion, matrix effects in urine remained substantial in 
the 100 μl assay. SIL-STEYGEGYACDTDLR spiked 
into urine gave an approximate 10-fold reduced signal 
when compared with when it was spiked into 50 mM 
Tris buffer pH 8, or endogenous STEYGEGYACDT-
DLR released from the digestion of a commercial uro-
modulin standard in the same buffer. This matrix sup-
pression is expected to drastically reduce the sensitivity 
of the assay. While a major focus of this assay was to 
provide the most simple method as possible, and with 
the high urinary uromodulin concentration in man 
meaning increased assay sensitivity was not required, 
a protein precipitation and acetone clean-up procedure 
has been described allowing quantitation of proteins 
in urine down to pg/ml concentrations [17]. Alterna-
tively a fractionation procedure has also resulted in uri-
nary protein quantification to an LLOQ of 10 pg per 
100 μg total urinary protein content [16].
While it was not an intention of this work to pro-
vide a high-throughput mass-spectrometric assay, the 
long chromatographic gradient of 152 min does result 
in poor sample throughput, especially when compared 
with the ELISA. Steepening the chromatographic gra-
dient and increasing the flow rate would reduce run-
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times. However, with the consequential shortening of 
peak widths through the use of very steep gradients 
and high flow rates, it must be ensured that sufficient 
data points are captured on the peaks to allow accurate 
analysis. Such analyses have however been reported 
using high-resolution mass spectrometers [40].
While in this study, a good correlation between the 
pseudo MRM and ELISA was observed for the quan-
tification of uromodulin in healthy volunteers, much 
improved correlations between mass-spectrometric 
and ELISA assays have previously been reported for 
other proteins in serum [41], and even in urine [42], 
albeit when fractionation was used. The pseudo MRM 
method however, quantified urinary uromodulin con-
centration in samples up to a maximum of 1.3 μM con-
centration, in contrast to the ELISA which quantified 
uromodulin in the same samples up to a maximum of 
699 nM. Similarly, the method described by Fu et al. 
also reported the mass-spectrometric assay to quan-
tify uromodulin at greater concentrations than the 
ELISA [27]. It is possible that the pH and ionic strength 
of the urine sample may have influenced the aggrega-
tion and precipitation of the protein in the ELISA, as 
uromodulin has been shown to precipitate under these 
conditions [3,43]. Commercial ELISA assays for the 
measurement of uromodulin include steps to normal-
ize sample pH to pH 8.0 to inhibit aggregation. This 
approach was also used in the pseudo MRM assay, pri-
marily as this is the optimal pH for trypsin efficiency. 
It should be noted however, that no change in the 
ELISA measurement of urinary uromodulin concen-
tration could be detected when samples were diluted in 
Tris-acetate buffer pH 8.0 [10].
Despite these differences in urinary uromodulin 
quantification by the two methods, a statistically sig-
nificant, approximate twofold increase in urinary uro-
modulin concentration was observed between individ-
uals harboring the CC and TT alleles of the rs4293393 
promoter variant. This is in accordance with previously 
reported studies [19,21]. This result further substantiates 
the biological relevance of the variant, and its poten-
tial influence on the high allelic frequency of the TT 
genotype.
Uromodulin is currently receiving increased interest 
as a potential biomarker of renal damage and tubular 
function. In these indices, urinary uromodulin con-
centration is reduced when compared with healthy 
individuals [8,23,44]. Furthermore, in certain advanced 
nephrological conditions, urinary uromodulin concen-
trations can be reduced to extremely low levels [23]. Con-
sequently, we sought to investigate whether our assay 
was able to identify and quantify urinary  uromodulin 
at these low concentrations. One clinical situation 
where extremely low urinary uromodulin concentra-
tions are consistently observed is in ADTKD-UMOD 
patients [23–26]. The pseudo MRM assay was able to 
quantify uromodulin in three out of the four patients 
assayed, although quantification relied on the use of 
only one surrogate peptide for the analysis of two of 
these patients. This indicates that the dynamic range of 
the pseudo MRM assay for  STEYGEGYACDTDLR is 
able to span almost the entire range of clinical urinary 
uromodulin concentrations. While the pseudo MRM 
was unable to quantify urinary uromodulin in one 
patient, the endogenous STEYGEGYACDTDLR pep-
tide could still be identified. The ELISA could quantify 
uromodulin in this sample indicating that it may still 
be of use in quantifying urinary  uromodulin concen-
trations falling out of range of the pseudo MRM assay. 
However, resolving the matrix effects of urine which 
were found to cause an approximate tenfold loss in 
signal for both surrogate peptides may allow sufficient 
increases in assay sensitivity to allow quantification of 
urinary uromodulin in this patient and both peptides 
to be used in the quantification of the other three. This 
investigation will constitute the next focus of our work.
In this study, we have reported a sensitive, accurate 
and precise measurement for the quantification of uro-
modulin in human urine. With the availability of the 
full fragment spectrum of the surrogate peptides using 
the pseudo MRM, complete confidence in the specific-
ity of the assay is assured. A further major advantage 
of the pseudo MRM assay over the ELISA is that it has 
the potential to allow the targeted analysis of multiple 
analytes in a single run. This is of particular interest in 
biomarker assessment, where panels of biomarkers are 
now often desired, potentially allowing the diagnosti-
cian further understanding into the site and mecha-
nism of tissue injury, as well as providing information 
into subsequent repair.
Future perspective
Each mass-spectrometric method for the quantification 
of proteins by MRM critically depends on the selection 
of appropriate candidate surrogate peptides. However, 
the strategies used for the selection of such peptides 
remain controversial. Traditional MRM assays are typi-
cally performed on triple-quad mass-spectrometers. The 
scan information to combine a precursor ion with spe-
cific fragment ions is obtained from mass-spectrometric 
analyses run in data-dependent mode. However, the 
transferal of these peptides from one mass-spectrometer 
to another is not straightforward. Alternatively, in silico 
predictions can be used but extensive subsequent valida-
tion of such peptides is required as again the behavior of 
the peptides on the mass-spectrometer is not assured. A 
major advantage of the pseudo MRM described here is 
that both data-dependent and quantitative analyses are 
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performed on the same instrument meaning these issues 
can be circumvented. A further advantage of the pseudo 
MRM method is that capture of the full fragmentation 
spectra of surrogate peptides allows complete confidence 
in the specificity of the assay. Furthermore, the extensive 
validation of the accuracy and precision of this method 
through following the FDA guidelines for bioanalytical 
method validation is also an approach not commonly 
used in quantitative proteomics; however, there is an 
increasing drive in the field for this validation to be 
taken up. In summary, the strategies used in developing 
this pseudo MRM may provide a useful template for 
the development of other quantitative proteomic assays 
in the future.
This accurate and reproducible method for the quan-
tification of urinary uromodulin also exhibits potential 
utility in the clinical diagnosis of renal function and 
injury. The most obvious example where this method 
could show clinical application is as an initial strategy 
to diagnose ADTKD-UMOD, prior to confirmation by 
genetic testing. In this situation, urinary concentration 
of uromodulin is greatly reduced when compared with 
the rest of the population. The protein is also receiving 
increasing interest as a marker of CKD and renal func-
tion. Furthermore, the specific expression of the protein 
in the thick-ascending limb of the loop of Henle may 
suggest that it could be a specific marker of damage at 
this site. Recent studies associating urinary uromodu-
lin concentration with markers of tubular function add 
further weight to this hypothesis. The pseudo MRM 
method described in this manuscript may represent an 
important tool in the further investigation of uromodu-
lin as a biomarker of renal injury. If these studies are 
successful, the method may then be incorporated into 
clinical diagnosis regimens. This will be facilitated by 
the simple transferal of the pseudo MRM method to 
much less expensive triple-quadrupole mass spectrom-
eters. These instruments can be used by people without 
extensive training, and will be represent great value in 
future clinical  diagnostic regimens.
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Executive summary
Background
• Uromodulin is almost universally quantified by ELISA, despite knowledge of the protein’s extensive 
glycosylation and aggregation which could affect its accurate measurement by this method.
• We have developed a pseudo MRM method for the absolute quantification of the protein in urine and 
compared quantification of urinary uromodulin in a human cohort with an established ELISA.
Results & conclusion
• Pseudo MRM can be used to perform protein quantification and surrogate peptide selection on the same mass 
spectrometer.
• Due to the capture of the full fragmentation scan the pseudo MRM allows complete specificity of the assay
• Selection of just two surrogate peptides allowed the accurate and reproducible quantification by the pseudo 
MRM method.
• Matrix effects of urine, leading to extensive loss of signal, were observed. Due to the high abundance of 
uromodulin in urine this did not affect the protein’s measurement, however further sample clean-up may be 
required for the quantification of less-abundant urinary proteins.
• The pseudo MRM method does not appear susceptible to stability and freeze–thaw issues affecting the ELISA.
Summary
• The pseudo MRM method described in this manuscript allows the accurate and reliable quantification of 
uromodulin in human urine and may be of value in future investigations into both the biological function of 
the protein and its potential utility as a biomarker of renal injury and function.
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